SAN FRANCISCO--(BUSINESS WIRE)--Freenome, a health technology company employing advanced machine learning to develop a blood test for early cancer detection, announced today that Randy Scott, Ph.D., has joined the company’s Board of Directors. Dr. Scott, who is Executive Chairman of Invitae Corporation (NYSE: NVTA), joins Freenome’s Board with CEO Gabriel Otte, COO Riley Ennis, and Vijay Pande, PhD, General Partner at Andreessen Horowitz.
“Randy is a pioneer in the genomics industry, and we’re confident that his deep expertise will help guide Freenome’s strategies as we look to focus on commercial applications for our technology in 2018,” said Mr. Ennis.
For nearly three decades, Dr. Scott has been an entrepreneur and visionary leader in genomic medicine. In 1991, he co-founded Incyte (NASDAQ: INCY), where he served as the chief scientific officer, president, and chairman. In 2000, he co-founded and led Genomic Health (NASDAQ: GHDX), a company focused on using genomic information to improve treatment decisions for patients with cancer. In 2012, Dr. Scott became co-founder and CEO of Invitae, one of the fastest growing genetic information companies, whose mission is to bring comprehensive genetic information into mainstream medical practice, before his appointment as Executive Chairman this year.
“I'm delighted to join the board of directors at Freenome because I believe it’s a unique company that sits at the intersection of artificial intelligence, genomics and healthcare with a unrelenting passion for helping patients,” said Dr. Scott. “Freenome's technology platform and approach are unique and have enormous potential across a large number of health applications in cancer and beyond.”
The author of 40 scientific publications and holder of 20 patents, Dr. Scott received a Bachelor of Science in Chemistry from Emporia State University and a Ph.D. in Biochemistry from the University of Kansas.
About Freenome
Freenome is a health technology company on a mission to empower everyone with the tools they need to prevent, detect, and treat their diseases. By applying advanced machine learning techniques to recent breakthroughs in genomic science, Freenome is currently developing noninvasive blood tests to detect early-stage cancer and make treatments more effective. In 2017, the company completed $72 million in Series A funding led by Andreessen Horowitz and including Google Ventures, Polaris Partners, and Founders Fund.
